Literature DB >> 2677406

Antibody reactivity to different regions of human T-cell leukemia virus type 1 gp61 in infected people.

Y M Chen1, T H Lee, K P Samuel, A Okayama, N Tachibana, I Miyoshi, T S Papas, M Essex.   

Abstract

The primary protein product of the human T-cell leukemia virus type 1 (HTLV-1) env gene, gp61, is cleaved to produce both the exterior (gp46) and the transmembrane (gp21) portions of the HTLV-1 envelope protein. To compare the reactivity with human antibodies of different regions of this gp61 protein, five plasmids (A, B, B1, C, and D) were constructed to express recombinant proteins (RPs) in Escherichia coli. RP-A, RP-B, RP-B1, and RP-C contain amino acid residues 26 to 165, 166 to 229, 166 to 201, and 229 to 308, respectively, of the exterior envelope protein gp46. Serum samples from HTLV-1-seropositive subjects were assayed for reactivity with these RPs by Western immunoblotting. The percentages of positive reactivity with each of the RPs were as follows: 18.9% (23 of 122) for RP-A, 89.6% (112 of 125) for RP-B, 70.2% (85 of 121) for RP-B1, and 92.9% (117 of 126) for RP-C. These results indicate that the C-terminal half of gp46 (RP-B plus RP-C) can detect 97.6% (123 of 126) of positive samples, while the N-terminal half of gp46 (RP-A) can only detect 18.9% of the HTLV-1-positive sera (P less than 0.005). Furthermore, RP-A, -B, and -C, which together span the entire length of gp46 except the first five amino acids at the N terminus and the last four amino acids at the C- terminus, detected 99.2% (125 of 126) of the HTLV-1-positive subjects. In contrast, RP-D, which contains the HTLV-1 transmembrane envelope protein gp21 minus the first amino acid at the N terminus, had a lower rate of antibody reactivity at 73.7% (84 of 114) (P less than 0.005). The difference in seropositive rates for RP-D between HTLV-1 carriers (55.6%) and adult T-cell leukemia patients (85.5%) is statistically significant (P less than 0.01). This study therefore indicates that the C-terminal half of gp46, especially the amino acid sequence from 200 to 308, contains the most reactive epitopes of the HTLV-1 gp61 envelope glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2677406      PMCID: PMC251144     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis.

Authors:  S Jacobson; C S Raine; E S Mingioli; D E McFarlin
Journal:  Nature       Date:  1988-02-11       Impact factor: 49.962

2.  Isolation of ras GTP-binding mutants using an in situ colony-binding assay.

Authors:  L A Feig; B T Pan; T M Roberts; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

3.  Polyomavirus small t antigen: overproduction in bacteria, purification, and utilization for monoclonal and polyclonal antibody production.

Authors:  D C Pallas; C Schley; M Mahoney; E Harlow; B S Schaffhausen; T M Roberts
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

4.  Envelope proteins of human T cell leukemia virus type I: characterization by antisera to synthetic peptides and identification of a natural epitope.

Authors:  T D Copeland; W P Tsai; Y D Kim; S Oroszlan
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

5.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

6.  Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion.

Authors:  R F Siliciano; T Lawton; C Knall; R W Karr; P Berman; T Gregory; E L Reinherz
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

7.  In vivo half-life of a protein is a function of its amino-terminal residue.

Authors:  A Bachmair; D Finley; A Varshavsky
Journal:  Science       Date:  1986-10-10       Impact factor: 47.728

8.  Human immunodeficiency virus type 1 has an additional coding sequence in the central region of the genome.

Authors:  Z Matsuda; M J Chou; M Matsuda; J H Huang; Y M Chen; R Redfield; K Mayer; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

9.  High-level expression vectors to synthesize unfused proteins in Escherichia coli.

Authors:  A Seth; P Lapis; G F Vande Woude; T Papas
Journal:  Gene       Date:  1986       Impact factor: 3.688

10.  Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection.

Authors:  H Shida; T Tochikura; T Sato; T Konno; K Hirayoshi; M Seki; Y Ito; M Hatanaka; Y Hinuma; M Sugimoto
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

View more
  18 in total

1.  Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus.

Authors:  L D Papsidero; R P Dittmer; L Vaickus; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

2.  Improvement of simultaneous detection of antibodies to Gag and envelope antigens of human T-lymphotropic virus type I by western immunoblot assay.

Authors:  H Miyakoshi; M Sugimoto; H Igarashi; H Honda; R Fujino; M Mizukoshi
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

3.  Comparison of immunofluorescence, particle agglutination, and enzyme immunoassays for detection of human T-cell leukemia virus type I antibody in African sera.

Authors:  M Verdier; F Denis; G Leonard; A Sangare; S Patillaud; M Prince-David; M Essex
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

4.  A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.

Authors:  J Arp; M LeVatte; J Rowe; S Perkins; E King; C Leystra-Lantz; S K Foung; G A Dekaban
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Diversity of intrathecal antibody synthesis against HTLV-I and its relation to HTLV-I associated myelopathy.

Authors:  B Kitze; K Usuku; S Izumo; M Nakamura; H Shiraki; S Ijichi; S Yashiki; T Fujiyoshi; S Sonoda; M Osame
Journal:  J Neurol       Date:  1996-05       Impact factor: 4.849

6.  Identification of functional regions in the human T-cell leukemia virus type I SU glycoprotein.

Authors:  L Delamarre; C Pique; D Pham; T Tursz; M C Dokhélar
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction.

Authors:  M D Lairmore; A M DiGeorge; S F Conrad; A V Trevino; R B Lal; P T Kaumaya
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Isolation of a human T-lymphotropic virus type I strain from Australian aboriginals.

Authors:  I Bastian; J Gardner; D Webb; I Gardner
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  Isolation and characterization of simian T-cell leukemia virus type II from New World monkeys.

Authors:  Y M Chen; Y J Jang; P J Kanki; Q C Yu; J J Wang; R J Montali; K P Samuel; T S Papas
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Sensitivity and specificity of a recombinant transmembrane glycoprotein (rgp21)-spiked western immunoblot for serological confirmation of human T-cell lymphotropic virus type I and type II infections.

Authors:  R B Lal; S Brodine; J Kazura; E Mbidde-Katonga; R Yanagihara; C Roberts
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.